Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.…
GH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility Output
Matinas BioPharma Holdings (NYSEAMERICAN: MTNB) is listed on NYSE American, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2 employees.
The shares were at 0.7999 USD on 20 November 2026, down 95.8% over 52 weeks. Its 52-week range is 0.7501 USD to 19.95 USD: the price is 96.0% below the high and 6.6% above the low.
Its market capitalisation is 890.71K USD.
Matinas BioPharma Holdings reports return on equity of -214.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 1.93M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.